164 related articles for article (PubMed ID: 33299234)
1. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.
Lesieur A; Thomas X; Nibourel O; Boissel N; Fenwarth L; De Botton S; Fournier E; Celli-Lebras K; Raffoux E; Recher C; Lambert J; Berthon C; Pigneux A; Itzykson R; Turlure P; Pautas C; Vargaftig J; Preudhomme C; Dombret H; Duployez N
Haematologica; 2021 Jun; 106(6):1767-1769. PubMed ID: 33299234
[TBL] [Abstract][Full Text] [Related]
2. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene.
Jeziskova I; Razga F; Toskova M; Dvorakova D; Timilsina S; Mayer J; Racil Z
Leuk Lymphoma; 2013 Apr; 54(4):867-70. PubMed ID: 22950897
[No Abstract] [Full Text] [Related]
3. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
[No Abstract] [Full Text] [Related]
4. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
[TBL] [Abstract][Full Text] [Related]
6. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.
Chou WC; Tang JL; Wu SJ; Tsay W; Yao M; Huang SY; Huang KC; Chen CY; Huang CF; Tien HF
Leukemia; 2007 May; 21(5):998-1004. PubMed ID: 17361227
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
[TBL] [Abstract][Full Text] [Related]
9. NPM1 for MRD? Droplet Like It's Hot!
Wertheim GBW; Bagg A
J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
[TBL] [Abstract][Full Text] [Related]
10. Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.
Folta A; Sasinkova M; Durinikova A; Drncova M; Weinbergerova B; Mayer J; Jeziskova I
Mol Biol Rep; 2022 Aug; 49(8):8169-8172. PubMed ID: 35716280
[TBL] [Abstract][Full Text] [Related]
11. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
[TBL] [Abstract][Full Text] [Related]
13. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
Papadaki C; Dufour A; Seibl M; Schneider S; Bohlander SK; Zellmeier E; Mellert G; Hiddemann W; Spiekermann K
Br J Haematol; 2009 Feb; 144(4):517-23. PubMed ID: 19055671
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (
Mutti M; Cordella S; Parisotto A; Bettelli F; Morselli M; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Giusti D; Colaci E; Cassanelli L; Paolini A; Martinelli S; Maffei R; Riva G; Nasillo V; Sarti M; Trenti T; Comoli P; Tagliafico E; Manfredini R; Eccher A; Lagreca I; Barozzi P; Potenza L; Marasca R; Candoni A; Luppi M; Forghieri F
Leuk Lymphoma; 2024 Apr; 65(4):511-515. PubMed ID: 38112426
[No Abstract] [Full Text] [Related]
15. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.
Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F
J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613
[TBL] [Abstract][Full Text] [Related]
16. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
17. Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis.
Calvo KL; Ojeda MJ; Ammatuna E; Lavorgna S; Ottone T; Targovnik HM; Lo-Coco F; Noguera NI
Eur J Haematol; 2009 Jan; 82(1):69-72. PubMed ID: 18801061
[TBL] [Abstract][Full Text] [Related]
18. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Sorigue M; Espasa A; Zamora L; Junca J
Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
[No Abstract] [Full Text] [Related]
19. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Schnittger S; Kern W; Tschulik C; Weiss T; Dicker F; Falini B; Haferlach C; Haferlach T
Blood; 2009 Sep; 114(11):2220-31. PubMed ID: 19587375
[TBL] [Abstract][Full Text] [Related]
20. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
